The culprit of mesalamine intolerance: case series and literature review
Open Access
- 31 July 2019
- journal article
- case report
- Published by Springer Nature in BMC Gastroenterology
- Vol. 19 (1) , 1-5
Abstract
Mesalamine is a first-line drug in the treatment of inflammatory bowel diseases, while its intolerance occasionally occurs in clinical practice. Most of adverse reactions are due to the active components, which may lead to step-up treatment, but excipients are sometimes regarded as the chief culprit and can be resolved by transferring to other preparations. Thus, distinguishing different kinds of intolerance is extremely important for clinical decision. Here we reported two cases with mesalamine intolerance. One patient with 5-aminosalicylic acid intolerance had similar adverse reactions to the treatment of different preparations, while another patient with excipients intolerance failed to tolerate Salofalk but could take Pentasa with no symptoms. Meanwhile, clinical manifestations were analysed and the previous reports referring to excipients intolerance were summarized. It is interesting to found that the patients with excipients intolerance mainly presented with acute skin symptoms, such as skin rash, urticaria and angioedema. But the adverse effects of 5-ASA in previous reports include fever, headache, rash, nausea, vomiting, dyspepsia, hepatotoxicity, pancreatitis, interstitial nephritis, pneumonitis, pericarditis and so on. 5-aminosalicylic acid and excipients should be taken into consideration together when mesalamine-related adverse events occur. Of note, a diagnosis of excipient intolerance should be paid more attention in the patients with the presentation of acute skin symptoms.Keywords
Funding Information
- National Natural Science Foundation of China (81570501, 81770554, 81772607, 81472311)
This publication has 34 references indexed in Scilit:
- Hypersensitivity to Generic Drugs with Soybean OilNew England Journal of Medicine, 2009
- Severe skin reaction due to excipients of an oral iron treatmentAllergy, 2007
- ORAL TOLERANCE OF CARBOXYMETHYLCELLULOSE IN PATIENTS WITH ANAPHYLAXIS TO PARENTERAL CARBOXYMETHYLCELLULOSEAnnals of Allergy, Asthma & Immunology, 2004
- Not all adverse drug reactions originate from active component: coloring agent-induced skin eruption in a patient treated with rifampicinAllergy, 2003
- Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2000
- Mesalazine-associated interstitial nephritis: twice in the same patient.Nephrology Dialysis Transplantation, 1997
- Eosinophilia from Food Dye Added to Enteral FeedingsNew England Journal of Medicine, 1990
- Mesalazine A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Chronic Inflammatory Bowel DiseaseDrugs, 1989
- ABSENCE OF ALLERGIC REACTION TO CYCLOSPORIN CAPSULES IN PATIENT ALLERGIC TO STANDARD ORAL AND INTRAVENOUS SOLUTION OF CYCLOSPORINThe Lancet, 1987
- HYPERSENSITIVITY TO TABLET ADDITIVES IN TRANSPLANT RECIPIENTS ON PREDNISONEThe Lancet, 1978